• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "September, 2015"
 Nascent Biotech, Inc. Announces an Agreement Reducing Its Liabilities By $1.4 Million
0
By Nascent Biotech
In Corporate News
Posted September 21, 2015

Nascent Biotech, Inc. Announces an Agreement Reducing Its Liabilities By $1.4 Million

San Diego, CA September 21, 2015 – Nascent Biotech, Inc. (“Nascent” or “the Company”) (PINK.BB: NBIO), reached an agreement with the licensor whereby the licensor will receive cash payments [...]

READ MORE
 Nascent Biotech Inc. Announces the Retirement of Its Convertible Debt
0
By Nascent Biotech
In Corporate News, News
Posted September 17, 2015

Nascent Biotech Inc. Announces the Retirement of Its Convertible Debt

San Diego, CA September 17, 2015 – Nascent Biotech, Inc, (“Nascent” or “the Company”) (PINK.BB: NBIO) is pleased to announce that it has retired the $ 60,000 convertible debenture effective [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.